Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $162.01 +1.33%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dutch Bros Inc. (BROS) Tops Q3 EPS by 1c; offers guidance
- Global Indemnity (GBLI) Misses Q3 EPS by 12c
- Lumen Technologies (LUMN) Misses Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
